Table 1.

Baseline characteristics of included studies

Authors name	Jiang et al.	Poujol-Robert et al.	Schwarzkopf et al.	Singh et al.
Country and year of publication	USA 2016	France 2014	Germany 2018	USA 2018
Type of study	Cross-sectional	RCS	PCS	RCS
Sample size	N = 1856	N = 188	N = 505	N = 592
Quality assessment	NOQ = 9	NOQ = 9	NOQ = 5	NOQ = 8
Study population	NHANES database was used to identify patients at risk of liver disease such as alcohol abuse, viral hepatitis and NASH.	HCV positive patient without HIV or HBV with transplanted liver between 2000 and 2010	Consecutive patients undergoing elective coronary angiography.	Patients with type 2 DM with biopsy-proven NAFLD
Baseline characteristics	Aspirin users	Recipient age = 52 ± 8	Anti-platelets users	Age = 52.2 ± 11.7
	Age = 46.6 ± 15.4	Recipient gender = 83% male	Age = 66 (58–75)	Sex = 62.7% female
	Sex = 55.4% male	Donor age = 48 ± 17	Sex = 82% male	Caucasians = 84.8%
	BMI = 29.6 ± 6.5	Donor gender = 70% male	BMI = 27(24–30)	BMI = 92% were overweight or obese
	Caucasians = 40% Diabetes = 11.5% HTN = 34.4% Non-aspirin users Age = 43.2 ± 14.7 Sex = 52% male BMI = 29.4 ± 6.5 Caucasians = 23.1 % Diabetes = 11.4% HTN = 27.8%	Diabetes = 75% HCV genotype 1=63%	Mean HbA1c = 6.1 Non-aspirin users Age = 66 (58–75) Sex = 82% male BMI = 27(24–30) Mean HbA1c = 5.9	Mean HbA1c = 6.4%
Methods to detect liver fibrosis	4 Non-invasive methods (FIB4, APRI, Forns and NFS) were used	Liver histology using METAVIR system	Fibroscan transient elastography	Histological evaluation of liver fibrosis
Anti-platelet agent used	Aspirin	Aspirin	Aspirin and/or P2Y12 receptor antagonists.	Aspirin
Outcome	Lower liver fibrosis scores in aspirin group	Lower risk of progression of fibrosis in aspirin group	Lower risk of progression of fibrosis in anti-platelets group	No beneficial effect of aspirin noted in preventing liver fibrosis